Telix Pharmaceuticals Limited and Mauna Kea Technologies are joining forces to expand their collaboration in urologic oncology surgery. The two companies have announced a strategic €6.0 million investment to develop new hybrid pharmaceutical-device products. This investment will combine Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio surgical endomicroscopy platform.
Mauna Kea Technologies is a leading medical device company that specializes in real-time intraoperative visualization of cancer tissue during surgery. Its Cellvizio confocal laser endomicroscopy platform has received regulatory approval and is suitable for a range of applications. Telix’s investment will support the development of advanced imaging techniques for minimally invasive surgery, particularly in the field of urologic oncology.
By using Telix’s radiopharmaceutical imaging agents such as TLX591-CDx (Illuccix) or TLX250-CDx (Zircaix) before surgery, surgeons can have improved surgical planning and determine the exact location and extent of the disease. Mauna Kea’s Cellvizio platform complements this by offering highly localized tissue visualization through endomicroscopic fluorescence detection, enabling surgeons to define and confirm surgical margins in real time.
As part of their long-term clinical and commercial partnership, Telix will acquire 19.33% of Mauna Kea’s ordinary shares through a reserved private placement. This investment reflects the shared commitment to combining Telix’s expertise in theranostic radiopharmaceuticals with Mauna Kea Technologies’ advanced medical devices to improve surgical techniques and clinical outcomes in urologic oncology.
Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies, believes that Cellvizio’s in vivo cellular visualization platform, combined with Telix’s portfolio of radiopharmaceutical diagnostics, surgical tools, and artificial intelligence, can offer powerful solutions for surgeons performing tumor resections. He welcomes Telix as a shareholder and looks forward to bringing their shared vision to fruition.
Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals, emphasized the companies’ commitment to expanding their partnership. The collaboration aims to develop cutting-edge technologies in targeted radiation, radio-guided surgery, and real-time cellular imaging to deliver significant improvements in surgical techniques and clinical outcomes.
The investment deal entails Telix purchasing 11,911,852 new ordinary shares of Mauna Kea at €0.5037 per share, giving Telix a 19.33% stake in the company.
Overall, the collaboration between Telix Pharmaceuticals and Mauna Kea Technologies represents a significant step forward in the field of urologic oncology surgery. By combining advanced imaging techniques with cancer-targeting agents, the partnership aims to provide surgeons with more precise tools and improve patient outcomes.
